[
    [
        {
            "time": "",
            "original_text": "周彩存教授：埃克替尼成为全球首个获批辅助治疗适应证的第一代EGFR TKI，EVIDENCE提供高级别循证医学证据",
            "features": {
                "keywords": [
                    "埃克替尼",
                    "全球首个",
                    "辅助治疗",
                    "EGFR TKI",
                    "EVIDENCE",
                    "循证医学证据"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "周彩存教授：埃克替尼成为全球首个获批辅助治疗适应证的第一代EGFR TKI，EVIDENCE提供高级别循证医学证据",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]